Dacarbazine,13,Dactinomycin,P11.5;C10B.18;C36.11,Darvon,P19.8,Daunomycin,C16.15,Death,2,Decadron,P17.14;P17.15;C05.21;C05.26;C27.7,Demerol,P19.8;P19.13,Dentist,P03.5,2-Deoxycoformycin,C18.23;C18.28,Department of Health and Human Services,P34.4,Desire,P23.3,Desmoid tumor,P35.15,Detoxification,P13.10;P13.11,Dexamethasone-,chr.p17.14;C24.19;C24.20;C28.20,Dexrazoxane,P35.17,Diabetes risk factor,C44.3;C45.4,Diagnosis,11,Diarrhea,3,Diazoxide,C15.13;C15.15,Dibenzyline,C01.15;C15.15,Dienestrol,P23.12,Diet best approach,11,Dietary therapies,P13.11,Diethylstilbestrol (DES),C35.29;C40.4;C46.2,Diffuse intermediate lymphocytic lymphoma,C24.14,Diflucan,P18.15,Difluorodeoxycytidine,P35.9,Digital rectal examination,P34.19,Dilantin,C05.26;C27.7,Dilatation and curettage (D&C),C43.12,Dilaudid,P19.8;P19.13,Diphenhydramine,chr.p17.14,Dipyridamole,P35.18;C31.11,Direct spread,P01.10,Disbelief,P29.5,Discharge planning,P26.3,Discovery,P29.6,Discrimination,P31.9,Diuretics,P17.23,DNA,P01.1;P01.6;P04.4;P36.1;P36.2;P36.3;P36.4,Doctor,4,Docusate sodium,P17.24,Donnatal,p17.31;P18.20,Dosimetrist,P06.4,Doubling times cancerous growth,1,Down's syndrome,C10A.5,Doxidan,P17.24,Doxorubicin,16,Doxycycline,C27.9,Droperidol,chr.p17.14,Drug patches,P19.13,Drugs,21,Dry mouth,P18.15,Ductal carcinoma,2,Dulcolax,P17.25,Duodenum diagram,C13.8,Durable Power of Attorney,P32.6,Dysgerminoma,C30.1,
for adrenal gland cancer,C01.16,for bone and soft tissue sarcomas,C36.11;C36.12;C36.18,for gastrointestinal cancer,C08.13,for Hodgkin's disease,C23.16,for islet cell carcinoma,C15.10,for mesothelioma,c26.16,for parathyroid cancer,C32.11,for small intestine cancer,C38.12,for stomach cancer,C39.25,for uterine cancer,C45.10;C45.12;C45.14,for vaginal cancer,C46.13,in hyperthermic perfusion,P11.5,side effects,chr.p17.13,coping with,P27.2;P27.3;P27.4;P27.7;P27.9;P27.10;P29.1;P29.3;P29.13;P29.14,preparing for,P27.10;P32.3;P32.5;P32.6,biopsy,P02.19;P02.21,40 blood tests,P02.6;P02.7,bone marrow analysis,P02.8,cytological studies,P02.19,endoscopy,P02.20;P02.21;P02.22,fluid tests,P02.8;P02.9,genetic,P36.9,imaging techniques,P02.17;P02.18;P02.19;P02.20;P02.21,physical examination,P02.4;P02.5,stool tests,P02.8,symptoms,P02.2,causes,P06.18;P17.28;P20.5,home care,P26.9,treatment,P17.28,calorie table,chr.p18.7,constipation,P17.25;P17.26,diarrhea,P17.28;P17.29,improving,P34.11,loss of appetite,P17.20;P17.21,nausea,P17.11;P17.12;P17.13;P17.14;P17.15,problems,P18.3;P18.4,radiation therapy,P18.14;P18.15;P18.16;P18.17;P18.18;P18.19;P18.20,risk factor,P34.6;P34.7;C11A.4;C12.4;C39.5;C42.1,sore mouth,P17.19,supplements,P18.8;P18.9;P18.11;P18.12,communicating with,P03.13;P03.14;P03.15;P03.16;P03.17;P30.7,role,P03.3;P03.4;P03.5,teamed with nurse,P15.6;P15.7,understanding,P03.9;P03.10;P03.11;P03.12,video,P01.3,for bladder cancer,C04.18;C04.24,for bone and soft tissue sarcomas,C36.11;C36.12;C36.13;C36.18,for breast cancer,C06.37;C06.48,for gastrointestinal cancer,C08.13,for head and neck cancer,C14B.17;C14B.19,for Hodgkin's disease,C23.21,for islet cell carcinoma,C15.12,for leukemia,C18.19,for mesothelioma,C26.11;C26.12;C26.16,for multiple myeloma,C28.12,for osteogenic sarcoma,C10D.8,for prostate cancer,C35.32,for small intestine cancer,C38.12,for thymus cancer,C41.10,investigational,P35.10;P35.12;P35.13;P35.17;P35.19,side effects,chr.p17.13,alkaloids,P07.6,alkylating agents,P07.6,antimetabolites,P07.6,antinausea,P17.14;P17.15,antitumor antibiotics,P07.6,approved uses,P35.6,causing nausea (table),chr.p17.13,clinical trials,P04.20;P07.2;P35.1;P35.2,colony-stimulating factors,P07.23,combinations,P07.3;P07.7;P35.5,hormones,P07.6,illicit,C16.6,investigational,P35.7;P35.8;P35.9;P35.10;P35.11;P35.12;P35.13;P35.14;P35.15;P35.16;P35.17;P35.18;P35.19,myths,P19.11;P19.12,non-cell-cycle-specific,P07.7,promoting cancer,P01.8,resistance to,P07.7,selection,P07.16;P07.17;P07.18;P07.19;P07.20,sensitivity,P07.17,sexuality,P23.8,treatment options,P19.10,breast,C06.3,prostate,C35.32,
